Sep 13, 2024
Currently, leading hidradenitis suppurativa drugs on the market include UCB Biopharma’s BIMZELX (bimekizumab), Novartis’ COSENTYX (secukinumab), and AbbVie/Eisai’s HUMIRA (adalimumab). HUMIRA dominated the market until 2023, despite its US composition-of-matter patent expiring in December 2016. AbbVie maintained a ...
Read More...
Sep 06, 2024
Hidradenitis suppurativa is a chronic inflammatory skin disease that affects the hair follicles and apocrine sweat glands. Hidradenitis suppurativa affects approximately 1% of the population, with women being more commonly affected than men. It often begins after puberty, usually in the 20s or 30s. In 2023, the ...
Read More...
Dec 01, 2023
The FDA recently approved Amgen’s Wezlana (ustekinumab-auub) for various inflammatory conditions, marking the first biosimilar approval referencing the popular J&J drug Stelara (ustekinumab). Wezlana, mirroring its reference product, is approved for treating multiple inflammatory diseases in adults, including m...
Read More...
Oct 28, 2022
Psoriatic arthritis (PsA) is a type of chronic inflammatory arthritis that affects approximately 1 in every 10 people with psoriasis. According to the National Psoriasis Foundation, psoriasis is most common in adults aged 30 to 50. However, psoriatic arthritis can develop at any age, including children. Accordin...
Read More...
Sep 23, 2022
Almost two decades ago, there were limited options for ulcerative colitis treatment. The readily available ulcerative colitis therapies were aminosalicylates and immunomodulators (azathioprine, 6-mercaptopurine, and methotrexate), with biologics (Adalimumab, Golimumab, infliximab, Ustekinumab, and Vedolizumab) rese...
Read More...
Dec 22, 2021
The Biosimilars market is growing at a breakneck pace. The biosimilar market provides a compelling economic value proposition. This has been a considerable element in expanding the biosimilar market, and the future of this sector appears promising. Many pharmaceutical companies from across the globe are proactively...
Read More...
Dec 15, 2021
Since the first biosimilar drug was approved in 2006, the EU has led the way in biosimilar regulation. Over the last decade, the EU has authorized the most biosimilars globally, gathering significant expertise with their usage and safety. Over ten years of clinical experience has shown that biosimilars licensed by ...
Read More...
Roche’s HER2-Positive Breast Cancer Treatment Franchise
Aug 13, 2024
Transforming Multiple Myeloma Treatment: The Promise of Novel Drug Classes
Jul 24, 2024
Newsletter/Whitepaper